$ATEC

MCGINNIS KAREN K sold $48K of ATEC

MCGINNIS KAREN K sold 6,050 shares of Alphatec Holdings, Inc. (ATEC) at $8.01 on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MCGINNIS KAREN K
Published Jun 12, 2026, 9:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATEC
Neutral
medium confidence
Mentioned
$ATEC
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATECNeutralLow
01

Why it matters

The disclosure confirms a director open-market sale of 6,050 shares at $8.01/share, executed under a pre-arranged 10b5-1 plan; it does not include any new operational, financial, or regulatory developments.

02

Market read

Traders may monitor for incremental insider activity, but this specific filing is unlikely to drive a major repricing without additional catalysts.

03

What to watch

Check for clustering of insider sales/buys around the same period; a single planned sale is less informative than a pattern.

Relevance 2/10Novelty 6/10Timing: Filed 2026-06-12; sale executed 2026-06-11

Background

The filing is an SEC Form 4 insider transaction for Alphatec Holdings, Inc. (ATEC).

Company-level read

Ticker impact

$ATECNeutralMedium confidence
Context

Alphatec director Karen McGinnis sold 6,050 shares in an open-market transaction on 2026-06-11 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; treat as low-signal unless follow-on insider activity accelerates.

Evidence & confidence

Form 4 is a primary disclosure, but the article provides no new company-specific catalyst beyond a planned sale.

Market effects

No sector-level read-across; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely mechanical; the market may overreact to the headline “sell” despite no change in fundamentals.

Key entities

  • Alphatec Holdings, Inc.

    Company whose director insider sale is disclosed on SEC Form 4.

  • Karen McGinnis

    Director who sold 6,050 shares under a 10b5-1 plan.

Related articles

$ATECMed

Alphatec Holdings, Inc. Q2 2026 Earnings Call Summary

Alphatec Holdings (ATEC) reported Q2 2026 results driven by 24% growth in new surgeon adoption and 20% procedural volume growth, lifting revenue 15%. Management kept full-year surgical revenue guidance at $805M and raised adjusted EBITDA guidance to $140M. It expects Q3 free cash flow of $4M to $6M and cites margin gains from inventory and supply chain efficiency.

$ATECMed

Alphatec Holdings, Inc. (ATEC): Results of Operations and Financial Condition

Alphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ATEC Reports Second Quarter Financial Results Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSB

$ATECMedAI 8/10

Here is Why Alphatec (ATEC) is One of the Best Cheap Stocks Under $10 to Buy in June

Alphatec Holdings (ATEC) reported Q1 2026 results on May 5, with total revenue up 14% to $192 million and surgical revenue up 17%. The company posted non-GAAP adjusted EBITDA of $21 million and said a new bank facility would cut annual interest expense by over $6 million and extend maturities to 2031. For 2026, it expects revenue of about $882 million and adjusted EBITDA of about $134 million.

$ATECMed

Alphatec Holdings, Inc. (ATEC): 12 Best Future Stocks to Buy Right Now.

Alphatec Holdings (ATEC) saw two analyst price-target cuts on May 7 while ratings stayed Overweight. Barclays lowered its target to $24 from $27, citing confidence in long-term growth despite near-term operational issues. Piper Sandler cut its target to $14 from $25 after first-quarter results missed expectations due to a weak EOS quarter and softer revenue per case from product mix headwinds.